Amrutanjan Health Care (AMRUTANJAN) Fundamentals 2026 — P/E 26.4x, Revenue Analysis | SniperIQ
Amrutanjan Health Care (AMRUTANJAN) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1,529 Crore, trading at ₹529.10 on the NSE. This SniperIQ fundamentals page covers Amrutanjan Health Care's valuation (P/E 26.4x, P/B 4.1x), profitability (net margin 11.5%), revenue (₹503 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Amrutanjan Health Care's market cap?
Amrutanjan Health Care (AMRUTANJAN) has a market capitalization of approximately ₹1,529 Crore, trading at ₹529.10 on the NSE. Market cap moves with the live share price.
What is Amrutanjan Health Care's P/E ratio?
Amrutanjan Health Care's trailing twelve-month P/E ratio is 26.4x, with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Amrutanjan Health Care?
Amrutanjan Health Care runs a net profit margin of 11.5%, a gross margin of 44.4%, and an operating margin of 13.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Amrutanjan Health Care generate?
Amrutanjan Health Care reported revenue of ₹503 Crore for fiscal year 2026, with net income of ₹58 Crore and earnings per share (EPS) of 20.03. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Amrutanjan Health Care pay a dividend?
Amrutanjan Health Care offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Amrutanjan Health Care financially healthy?
Amrutanjan Health Care carries a debt-to-equity ratio of 0.00x and a current ratio of 2.31x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Amrutanjan Health Care a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amrutanjan Health Care (AMRUTANJAN) the key facts are: market cap ₹1,529 Crore, P/E 26.4x, revenue ₹503 Crore, 52-week range 486-790.95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Amrutanjan Health Care's full fundamentals live
Get Amrutanjan Health Care's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.